IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia

Assessment of the IgG Trough Level in Subjects With Primary Immunodeficiency Switching From Standard Subcutaneous Immunoglobulin (SCIG) to Every Other Week HyQvia

Most immunodeficiencies are related to severe immunoglobulin deficiencies which require lifelong replacement therapy with immunoglobulin G (IgG) to reduce the incidence and severity of infections. IgG can be administered intravenously (IGIV) every 21 or 28 days or subcutaneously every week or every other week (IGSC) for subjects who do not tolerate IV infusions or have difficulties with venous access. No head-to-head data are available to directly compare HyQvia with conventional SCIG. However, SCIG is indicated for administration frequencies from daily up to every other week dosing while HyQvia is indicated for infusion frequencies every 2-4 weeks. This study is designed to assess the IgG trough level after switching from standard SCIG to every other week HyQvia and HyQvia every 3-4 weeks

Study Overview

• Status: Completed
• Conditions: Primary Immunodeficiency
• Intervention / Treatment: Drug: IgHy10

Detailed Description

Open-label, one arm study conducted in France in subjects with PI to IgG trough level at steady state after standard SCIG dosing and after HyQvia administered every other week and every 3-4 weeks at equivalent dose. The study will have three periods:

• The first period is a one-week ramp-up period. The first administration of HyQvia will be with a one-week dose as specified in the summary of product characteristics of HyQvia.
• During the first three-month follow-up period, HyQvia will be administered, every other week at a dose equivalent to the dose administered with the previous treatment (standard SCIG).
• At the end of this first follow-up period, the dose of HyQvia will be increased for the next infusion to reach a 3-week equivalent dose. If it this volume is well tolerated, the following dosing will be a 4-week equivalent dose. HyQvia will then be administered every 3 or 4 weeks for three months.

• Study Type: Interventional
• Enrollment (Actual): 22
• Phase: Phase 4

Contacts and Locations

Study Locations

• France
  • Lille, France
    • CHRU, Hôpital Claude Huriez
  • Marseille, France, 13005
    • Hôpital de La Conception
  • Nantes, France, 44093
    • CHU de Nantes - Hotel Dieu
  • Paris, France, 75015
    • Hopital Necker
  • Paris, France, 75010
    • Hôpital St Louis
  • Pessac, France, 33604
    • Hopital Haut Leveque
  • Strasbourg, France, 67000
    • CHU de Strasbourg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female subject at least 18 years old at the time inclusion.
• Suffering from PI requiring immunoglobulin replacement therapy.
• Treated with SCIG at stable dose for at least 3 months at the time of inclusion.
• Well balanced SCIG treatment according to the investigator at the time of inclusion.
• If female of childbearing potential, the subject must have a negative blood or urine pregnancy test at the time of inclusion and must agree to employ adequate birth control measures during the whole study.
• Willing and able to comply with the requirements of the protocol.
• Having signed the informed consent form.

Exclusion Criteria:

• Known history of chronic kidney disease, or glomerular filtration rate (GFR) of <60 mL/min/1.73m2 estimated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at the time of screening.
• Having received a chemotherapy or immunomodulating therapy for either malignant or chronic inflammatory disease for over 6 months.
• Receiving anticoagulant therapy.
• Having abnormal protein loss (protein losing enteropathy, nephrotic syndrome).
• Know allergy to hyaluronidase.
• Family member or employee of the investigator.
• Having participated in another interventional clinical study involving an investigational product (IP) or investigational device within 30 days prior to inclusion or scheduled to participate in another clinical study involving an another investigational product or investigational device during the course of this study.
• If female, pregnant or breastfeeding at the time of enrolment.
• If female, planning to become pregnant during the time period of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: IgHy10 (HyQvia); Open-label, one arm study conducted in France in subjects with PI to IgG trough level at steady state after standard SCIG dosing and after IgHy10 (HyQvia) administered every other week and every 3-4 weeks at equivalent dose. The study will have three periods: The first period is a one-week ramp-up period. The first administration of IgHy10 (HyQvia) will be with a one-week dose; During the first three-month follow-up period, IgHy10 (HyQvia) will be administered, every other week at a dose equivalent to the dose administered with the previous treatment (standard SCIG).; At the end of this first follow-up period, the dose of IgHy10 (HyQvia) will be increased for the next infusion to reach a 3-4 week equivalent dose.

Drug: IgHy10; Sub Cutaneous IgHy10 administration; Other Names: HyQvia

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The primary endpoint is the change in IgG trough level at 3 months (visit 3) as compared to baseline (visit 1).	Every 2 weeks during the baseline (visit 1) and the 3 months (visit3)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of adverse reactions		6 months
The change in IgG trough level at 6 months (visit 4) as compared to baseline (visit 1) and 3 months (visit 3).		Every 3 weeks after the 3 months (visit 3) as 6 months ( visit 4)
Incidence rate of adverse reactions		6 months
Number of infection		6 months
The Short Form (36) Health Survey	standardized test for measuring the quality of life	at 6 months
Treatment Satisfaction Questionnaire for Medication (TSQM-9).		at 6 months

Collaborators and Investigators

• Sponsor: University Hospital, Lille
• Collaborators: Shire
• Investigators: Principal Investigator: Eric Hachulla, MD, PhD, University Hospital, Lille

Study record dates

Study Major Dates

• Study Start (Actual): November 11, 2016
• Primary Completion (Actual): March 16, 2018
• Study Completion (Actual): November 1, 2018

Study Registration Dates

• First Submitted: August 17, 2016
• First Submitted That Met QC Criteria: August 23, 2016
• First Posted (Estimate): August 29, 2016

Study Record Updates

• Last Update Posted (Actual): June 25, 2019
• Last Update Submitted That Met QC Criteria: June 24, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Keywords: Primary Immunodeficiency; SubCutaneous Immunoglobulins
• Additional Relevant MeSH Terms: Immune System Diseases; Genetic Diseases, Inborn; Immunologic Deficiency Syndromes; Primary Immunodeficiency Diseases
• Other Study ID Numbers: 2015_31; 2016-001480-36 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No